Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Tommy, I'm on board with your logic here.
I dont think we can apply a distribution from one trial to another, but would agree that if SNG are allowed to combine data from trials (in the same setting) then there is a very good chance they get to an appropriate p value, as you demonstrated. Hopefully that can be used by the company.
With the dose thing, someone answered that (AZs vaccine). I still wonder about the change of device, if that precludes them from combining, but hopefully that's not a problem.
Let's see what we get in three weeks!
Nice work Tommy.
That's a fair assumption and gives a great result!
Anyone know of any cases where P2 data has been used to bolster P3 data? Would regulators accept that?
I cant remember, did we change the dose between trials? Crap I think we did, and nebuliser.
Thinking of it, could that 'inferior' nebuliser have had a negative effect on the p3 trial?
Still great news, shows a very strong, very important signal.
Let's hope they can legerage something like this.